PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP

Objectives: Pirtobrutinib is a highly selective, non-covalent (reversible) BTK-inhibitor (BTKi). Here, we report updated results of pirtobrutinib in patients (pts) with cBTKi pre-treated relapsed/refractory (R/R) mantle cell lymphoma (MCL) and more than 3 years follow-up from start of enrollment. Ma...

Descrizione completa

Dettagli Bibliografici

Autori principali:	NN Shah, PL Zinzani, TA Eyre, K Izutsu, AJ Alencar, K Patel, T Munir, DE Tsai, ML Wang, LYGN Presenter
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2023-10-01
Serie:	Hematology, Transfusion and Cell Therapy
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2531137923008672
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!